£10 million funding boost for digital therapeutic start-up 

Founded five years ago, Strolll has recently announced £10.35 million Series A funding round led by IW Capital.

With Reality DTX, Strolll has developed a cutting-edge digital therapeutic software for augmented reality glasses and headsets to enable home-based neurorehabilitation for patients with neurological conditions.

Strolll will use the investment to accelerate its sales and marketing activities, extend its product leadership and to expand its regulatory label, which will allow the company to target additional neuro-related disorders adjacent to the ones it already addresses.

Results from Strolll’s clinical trials, published in early 2024, show it to be a safe, well accepted and effective treatment. It has an 8.8/10 usability scores, and 104% patient adherence rate to high intensity neurorehabilitation that has led to significant improvement in patients’ gait and balance.

The trial also found that clinicians using the technologies were able to offer up to seven times more treatments with 67% less staff time, enabling health care services to provide patient care more effectively and efficiently (1).

Health Innovation East has been working with Strolll since 2022, providing mentoring for corporate and commercial needs, giving advice on market entry and connecting Strolll with key NHS colleagues in the East of England.

Last year, Strolll commenced a three-year, £2.4 million project grant-funded by the National Institute for Health and Care Research (NIHR) with the University of Leeds, University of York and four leading NHS trusts across the UK to conduct randomised controlled trial of Strolll as a therapeutic treatment for patients with Parkinson’s disease in real-world healthcare settings.

Commenting on the investment, IW Capital’s Investment Director, Isobel Egemole, says, “IW Capital are thrilled to announce our investment into Strolll. Strolll are transforming the physiotherapy and neurorehabilitation markets and have already helped a significant number of people with debilitating neurological disorders to live better lives. The potential impact of their software is huge and we’re proud to be backing this cutting-edge business as it addresses key healthcare needs.” 

Jorgen Ellis, CEO of Strolll said, “Strolll are at an exciting inflection point in our journey and we are delighted to be partnering with IW Capital, as well as other investment partners, as we look to accelerate the growth of our business. We are positioned at the forefront of the neurorehabilitation market and we’re passionate about helping to improve the care that patients with neurological disorders receive. We thank investors for believing in our vision of healthcare and we look forward to building on our achievements to date.” 

References: 

(1) Geerse DJ, Coolen B, van Hilten JJ, Roerdink M (2021). Holocue: a wearable holographic cueing application for alleviating freezing of gait in Parkinson’s disease Frontiers in Neurology | doi: 10.3389/fneur.2021.628388.